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Abstract
Background: Multiplex polymerase chain reaction (mPCR) enables recovery of viruses from airways of patients with
community-acquired pneumonia (CAP), although their clinical impact remains uncertain.
Methods: Among consecutive adult patients who had undergone a mPCR within 72 hours following their
admission to one intensive care unit (ICU), we retrospectively included those with a final diagnosis of CAP. Four
etiology groups were clustered: bacterial, viral, mixed (viral-bacterial) and no etiology. A composite criterion of
complicated course (hospital death or mechanical ventilation > 7 days) was used. A subgroup analysis compared
patients with bacterial and viral-bacterial CAP matched on the bacterial pathogens.
Results: Among 174 patients (132 men [76 %], age 63 [53–75] years, SAPSII 38 [27;55], median PSI score 106 [78;130]),
bacterial, viral, mixed and no etiology groups gathered 46 (26 %), 53 (31 %), 45 (26 %) and 30 (17 %) patients,
respectively. Virus-infected patients displayed a high creatine kinase serum level, a low platelet count, and a trend
toward more frequent alveolar-interstitial infiltrates. A complicated course was more frequent in the mixed group
(31/45, 69 %), as compared to bacterial (18/46, 39 %), viral (15/53, 28 %) and no etiology (12/30, 40 %) groups (p < 0.01).
In multivariate analysis, the mixed (viral-bacterial) infection was independently associated with complicated course
(reference: bacterial pneumonia; OR, 3.58; CI 95 %, 1.16–11; p = 0.03). The subgroup analysis of bacteria-matched
patients confirmed these findings.
Conclusions: Viral-bacterial coinfection during severe CAP in adults is associated with an impaired presentation and a
complicated course.
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Background
Community-acquired pneumonia (CAP) is a common
disease that may become severe, leading to admission to
intensive care units (ICU) [1]. CAP etiology is usually
bacterial; however, the causative role of respiratory vi-
ruses emerged recently [2]. Multiplex polymerase chain
reaction (mPCR) kits screen a large panel of respiratory
viruses, and nowadays are available in clinical practice.
They were used within several studies among adult ICU
patients with CAP [3–6]. High rates of positivity were
reported, up to 49 % [4], with strong variations in the
distribution of viral species according to the population,
the season, and the geographic area. However, the
causative role of respiratory viruses identified in the
respiratory tract during pneumonia is still debatable,
since respiratory viruses might be present in asymptom-
atic adult subjects [7, 8]. Some experimental data
focusing on virus-bacteria interactions during respiratory
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tract infections supported a pathogenic role of respiratory
viruses during pneumonia [9]. In mice, the coinfection of
influenza with S. pneumoniae [10], L. pneumophila [11] or
S. aureus [12] impaired the anti-influenza immune
response and increased the mortality. Similar synergistic
results are obtained with S. pneumoniae and respiratory
syncytial virus [13], or S. pneumoniae and rhinovirus [14].
In humans, the pathogenic role of respiratory viruses
in virus-bacteria coinfected patients remains unclear.
We conducted a comprehensive observational study
among adult ICU patients with CAP, to compare clinical
characteristics, biological presentation, and outcome ac-
cording to the presence of virus in the respiratory tract.
Methods
Study design and patient selection
We conducted a retrospective monocenter observational
study in the 26-bed ICU of the Bichat Claude Bernard
University Hospital (Paris, France). During the study
period, all consecutive patients having undergone a
mPCR in the respiratory tract within the 72 hours
following their ICU admission were screened. Medical
records were independently reviewed by two physicians.
All patients with a final diagnosis of pneumonia were
included (see definitions for population selection in
Additional file 1).
Data collection
AT ICU admission and during ICU stay, data regard-
ing demographics, comorbidity, clinical examinations,
laboratory and radiological findings, microbiologic investi-
gations, and therapeutic management were collected (for
details, see Additional file 1). Mortality was defined as
death from any cause within 30 days of hospitalization.
Pneumonia severity was assessed through the Pneu-
monia Severity Index (PSI) [15], and the Simplified
Acute Physiologic Score (SAPS) II [16].
Microbiological evaluation
Respiratory tract specimens underwent Gram staining and
quantitative culture for bacterial pathogens. Urine antigen
testing of S. pneumoniae and L. pneumophila used the
BinaxNOW kits (Alere, Jouy en Josas, France). The
immunoglobulin (Ig) antibodies testing for C. pneumoniae
and M. pneumoniae was considered positive if IgM anti-
bodies were identified or if a significant increase in IgG
antibodies was observed between paired serum samples.
The respiratory mPCR were performed either in
nasopharyngeal (NP) swabs or in lower respiratory tract
(LRT) specimens, usually bronchoalveolar lavage fluid
otherwise endotracheal aspirate. During the study
period, different mPCR kits were used (for details, see
Additional file 1). Respifinder® 19 (Pathofinder, Maastricht,
The Netherlands) and Filmarray Respiratory Panel
(BioFire Diagnostics, Salt Lake City, UT, USA) could not
detect bocavirus nor differentiate rhinovirus and entero-
virus; therefore, rhinovirus and enterovirus results were
grouped as picornavirus (rhinovirus).
Either in blood samples or in bronchoalveolar lavage
fluid, the cytomegalovirus PCR used the CMV R-gene® kit
(Argene, Verniolle, France ) or the QS-RGQ® kit (Qiagen,
Hilden, Germany), and the herpex simplex virus PCR used
LightCycler® HSV (Roche, Basel, Switzerland).
Classification of patients according to pathogens
A bacterium was considered as a causative pathogen of
the pneumonia if this bacterium fulfilled at least one
criterion (for details, see Additional file 1). A virus
identified with PCR was always considered as a causative
pathogen of the pneumonia.
Pneumonia was defined as: (i) bacterial, if microbio-
logical investigations revealed at least one bacterium and
no virus; (ii), viral, if microbiological investigations
revealed at least one virus and no bacterium; (iii) mixed
(virus-bacteria), if microbiological investigations revealed
at least one virus and one bacterium; and (iv) no
etiology, if microbiological investigations revealed no
virus and no bacterium.
Endpoints
The primary endpoint was to identify presentation and
prognosis-specific features in virus-bacteria coinfected
patients. Comparisons focused on microbiological data,
biological findings and radiological patterns on admis-
sion, ICU course and hospital outcome. A composite
criterion named “complicated course” included hospital
death or mechanical ventilation for more than 7 days.
The second endpoint was to describe the epidemiology
of respiratory viruses in adult patients admitted to the
ICU for a CAP. Patients were clustered into four groups
according to the microbiological etiology of pneumonia:
bacterial, viral, mixed, and no etiology.
Matching procedure
To better control for impact of the bacterial pathogen on
our main findings, we also designed a subgroup analysis
comparing patients with bacterial and mixed viral-
bacterial CAP, matched on the bacterial pathogen. If more
than one bacterium was identified in cases, we sought for
a control with the same bacterial combination.
Data presentation and statistical analysis
Continuous data were expressed as median [first
through third quartiles] and were compared using the
Kruskall-Wallis test followed by pairwise Mann-Whitney
test. Categorical data were expressed as number
(percentages) and were evaluated using the chi-square
test or Fisher’s exact test. p values less than 0.05 were
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considered significant. A univariate logistic regression
with clinically relevant variables was used to identify
variables associated with a complicated course. A multi-
variate conditional logistic regression, including variables
with p value less than 0.10 in the previous step, was used
to identify variables independently associated with
complicated course. Similar statistical analyses were
performed to identify variables independently associated
with hospital death and mechanical ventilation for more
than 7 days in survivors at day 28. Quantitative variables
that did not validate the log-linearity assumption were
transformed into categorical variable according to their
median value. Missing data were imputed to the median
or to the more frequent value. The accuracy of the final
model was tested using area under the receiver operating
characteristic curve analysis and the Hosmer-Lemeshow
chi-square test. An additional multivariate conditional
logistic regression, limited to bacterial and mixed groups,
was performed to search specifically for an association
between virus-bacteria coinfection and complicated
course. Comparisons in the subgroup analysis of bacteria-
matched patients involved univariate conditional logistic
regression followed by multivariate conditional logistic
regression to assess associations between microbiological
diagnosis and complicated course, adjusting for clinically
relevant variables. Analyses were performed using the SAS
software package (SAS Institute, Cary, NC, USA).
Results
Population
From October 2011 to June 2015, 752 patients were
screened (Fig. 1). The final study group consisted of 174
patients (132 men (76 %), age 63 [53–75] years, SAPS II
38 [27;55]) (Table 1). One third (33.3 %) were referred
from medical wards or another ICU. The median PSI
score at hospital admission was 106 [78;130]. Pneumonia
was considered health care-associated pneumonia in
nearly half the patients (49.4 %). At least one factor of
immunosuppression was present in 32.8 % of patients.
Microbiological diagnosis
The microbiological investigations are displayed in
Additional file 1: Table S1. The microbiological findings
are displayed in Table 2. mPCR was performed in NP
swabs exclusively (n = 110, 63.2 %) or in LRT specimen
exclusively (n = 43, 24.7 %) or both (n = 21, n = 13.2 %).
Respiratory tract specimens for bacterial culture have
been obtained in 153 (87.9 %) patients. In 34 (19.5 %)
patients the only respiratory tract specimen that has
been obtained was sputum. Near half the patients (n = 77,
44.3 %) received antibiotics prior to referral.
A microbiological documentation was obtained in 144
(82.8 %) patients. At least one bacterium was identified
in 91 (52.3 %) patients and at least one virus in 98
(56.3 %) patients. Bacterial documentation was obtained
in 56 (57.7 %) patients who had not been exposed to
antibiotics prior to referral, compared to 35 (45.5 %)
antibiotics-exposed patients (p = 0.13). S. pneumoniae
was the most commonly identified bacterium, found in
40 (23 %) patients. Of these 40 patients, S. pneumoniae
was cultured in blood in five patients. In 22 (12.6 %)
patients, more than one bacterial species was identified.
Taken together, Pseudomonas aeruginosa and Enterobac-
teriaceae species were identified in nine (19.5 %) patients
of the bacterial group and nine (19 %) patients of the
mixed group.
Influenza viruses and picornavirus (rhinovirus) were the
most commonly identified viruses, found in 38 (21.8 %)
and 22 (12.6 %) patients, respectively. In nine (5.2 %)
patients, more than one virus was identified. In the 21
patients having undergone mPCR in both NP swabs and
LRT specimen, the mPCR were discordant in ten patients,
including eight patients with a NP mPCR positive and a
LRT mPCR negative and two patients with a NP mPCR
negative and a LRT mPCR positive.
Analysis according the microbiological diagnosis
The four study groups did not differ in terms of demo-
graphics, comorbid conditions, chronic immunosuppres-
sion, HCAP factors, incidence of transfer from another
ward, and antibiotics before referral (Table 1). The micro-
biological investigations also were similar (Additional file 1:
Table S1). S. pneumoniae was the predominant bacterium
in both bacterial and mixed groups (Table 2). Only one
patient was infected with extended-spectrum beta-
lactamase-producing Enterobacteriaceae. Fourteen patients
were infected with intracellular bacteria, including L. pneu-
mophila, C. pneumoniae and M. pneumoniae, but only two
had a viral coinfection. Influenza viruses were the most
commonly viruses in the viral group, whereas picornavirus
(rhinovirus) and influenza viruses were equally predomin-
ant in the mixed group.
The incidence of shock was higher in patients with a
documented bacterial infection (30.4 % and 24.4 % in
bacterial and mixed group, respectively) in comparison
with other patients (5.7 % and 13.3 % in viral and no
etiology groups, respectively, p < 0.01) (Table 1). Overall,
patients with mixed pneumonia displayed a higher
disease severity on hospital and ICU admission, with
higher rate of PSI class IV-V at hospital referral (80 % vs.
67.4 %, 62.3 % and 46.7 % in bacterial, viral, and no
etiology groups, respectively, p = 0.03) and increased
SAPS II (46 vs 39, 36 and 33 in bacterial, viral, and no
etiology groups, respectively, p = 0.02).
Among the 45 patients with mixed pneumonia, 30
were infected with viruses other than influenza, includ-
ing 14 patients infected with picornavirus (rhinovirus).
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Virus-infected patients displayed high serum levels of
creatine kinase, a low platelet count and a trend toward
a high incidence of alveolar-interstitial infiltrates on
chest X-ray (Additional file 1: Table S2). No significant
difference was observed between groups regarding
cardiac troponin T. However, 20 (20.4 %) virus-infected
patients displayed a cardiac troponin T above the upper
limit of normal, compared to eight (10.5 %) virus-
uninfected patients.
All the bacteria-infected patients, except one in the
bacterial group (45/46, 97.8 %) and one in the mixed
group (44/45, 97.8 %), received an appropriate antimicro-
bial regimen within the first 24 hours of ICU admission.
Among the influenza-infected patients, most patients (32/
38, 84.2 %) received ozeltamivir within the first 24 hours
of admission to ICU. Complicated course was more
frequent in the mixed group (31/45, 68.9 %), as compared
to bacterial (18/46, 39.1 %), viral (15/53, 28.3 %), and no
etiology (12/30, 40 %) groups (p < 0.01). In multivariate
analysis, the microbiological diagnosis was identified as an
independent factor of complicated course (Table 3). The
microbiological diagnosis was not independently associ-
ated with hospital death (Additional file 1: Table S3) but
with mechanical ventilation for more than 7 days in
survivors at day 28 (Additional file 1: Table S4). The
additional multivariate analysis, limited to bacterial and
mixed groups, identified the virus-bacteria coinfection as
independently associated with the complicated course
(reference: bacterial pneumonia; OR, 3.56; CI 95 %,
1.24–10.18; p = 0.02) (Table 4). The impact of the viral
coinfection was similar for influenza and other viruses
(Additional file 1: Table S5). The subgroup analysis of
bacteria-matched patients confirmed these findings
(Additional file 1: Table S6).
Discussion
This retrospective study investigated the impact of the
mixed viral-bacterial coinfection on the presentation and
outcome of ICU patients with CAP. Real-time mPCR
tests identified at least one virus in the respiratory tract
of 56.3 % of patients. Specific biological and radiographic
features, including high serum levels of creatine kinase,
a low platelet count, and a high incidence of alveolar-
interstitial infiltrates were observed in these patients,
who presented also the higher status severity on hospital
admission and the higher frequency of hemodynamic
and respiratory failures during ICU stay. The viral-
bacterial coinfection was independently associated with
a complicated course. These findings were confirmed by
a subgroup analysis comparing bacteria-infected and
virus-bacteria coinfected patients.
In this study, more than one patient out of two
(56.3 %) were infected with at least one virus, in line
with a recent report on ICU ventilated patients with
CAP [4]. This finding illustrated the high yield of an
aggressive diagnostic strategy with a broad panel mPCR
Fig. 1 Flow chart. a All consecutive patients admitted to the ICU during a 3.5-year period and having undergone a mPCR on a respiratory tract
sample within 72 hours following ICU admission were screened. b Acute bronchial disease included COPD exacerbation, asthma, and acute
bronchitis. c Pneumonia was considered hospital-acquired if neither clinically present nor in an incubation period at time of hospital admission
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Age, y 63 [53;75] 64 [53;75] 64 [54;75] 63 [54;75] 66 [57;78] 0.85
Sex, male 132 (75.9) 37 (80.4) 38 (71.7) 33 (73.3) 24 (80) 0.69
Weight, kg 71 [62;82] 70 [60;80] 71 [64;84] 70 [60;77] 75 [62;83] 0.64
Smoking 53 (31.7) 16 (37.2) 16 (30.8) 13 (30.2) 8 (27.6) 0.83
McCabe score > 1 38 (21.8) 7 (15.2) 13 (24.5) 12 (26.7) 6 (20) 0.56
WHO performance status > 0 53 (33.5) 10 (22.7) 19 (41.3) 14 (35.9) 10 (34.5) 0.30
Chronic immunosuppression 57 (32.8) 16 (34.8) 21 (39.6) 14 (31.1) 6 (20) 0.32
HIV 14 (8) 7 (15.2) 3 (5.7) 3 (6.7) 1 (3.3) 0.20
Steroid therapy 19 (10.9) 2 (4.3) 10 (18.9) 6 (13.3) 1 (3.3) 0.06
Other immunosuppressive 21 (12.4) 3 (6.5) 10 (20) 7 (15.6) 1 (3.4) 0.08
Solid organ transplantation 14 (8) 2 (4.3) 5 (9.4) 6 (13.3) 1 (3.3) 0.31
Cancer 15 (8.6) 6 (13) 4 (7.5) 2 (4.4) 3 (10) 0.51
Chronic diseaseb 86 (49.4) 20 (43.5) 34 (64.2) 20 (44.4) 12 (40) 0.08
Coronary artery disease 27 (15.5) 6 (13) 9 (17) 9 (20) 3 (10) 0.64
HCAPc 86 (49.4) 22 (47.8) 31 (58.5) 22 (48.9) 11 (36.7) 0.29
Transfer from another wardd 58 (33.3) 14 (30.4) 19 (35.8) 17 (37.8) 8 (26.7) 0.72
Antibiotics before ICU admissione 77 (44.3) 15 (32.6) 30 (56.6) 19 (42.2) 13 (43.3) 0.12
Organ failures on ICU admission
Glasgow < 15 42 (24.1) 14 (30.4) 11 (20.8) 11 (24.4) 6 (20) 0.66
Shock 32 (18.4) 14 (30.4) 3 (5.7) 11 (24.4) 4 (13.3) <0.01
PaO2/FIO2 ratio 174 [130;230] 173 [130;229] 172 [122;227] 165 [134;228] 200 [165;252] 0.22
SAPS II score 38 [27;55] 39 [32;60] 36 [26;48] 46 [34;59] 33 [18;46] 0.02
PSI score at hospital referral 106 [78;130] 110 [84;152] 98 [82;128] 119 [98;126] 89 [70;121] 0.12
PSI class IV-V at hospital referral 114 (65.5) 31 (67.4) 33 (62.3) 36 (80) 14 (46.7) 0.03
Organ supports during ICU stay
Noninvasive ventilation 55 (31.8) 14 (30.4) 21 (40.4) 12 (26.7) 8 (26.7) 0.44
Mechanical ventilation 98 (56.3) 28 (60.9) 22 (41.5) 36 (80) 12 (40) <0.01
ARDS 60 (34.5) 17 (37) 13 (24.5) 22 (48.9) 8 (26.7) 0.06
Dialysis 37 (21.3) 10 (21.7) 10 (18.9) 12 (26.7) 5 (16.7) 0.72
Vasopressors 80 (46.2) 22 (47.8) 19 (36.5) 27 (60) 12 (40) 0.12
Outcome
Length of mechanical ventilation, d 9 [5;13] 6.5 [3;12.5] 7 [4;12] 9 [6;14] 10 [7.5;17.5] 0.34
Follow-up duration, df 15 [10 ; 29] 14 [5;23] 18 [12;32] 16 [11;31] 14.5 [12;19] 0.25
Hospital mortality 30 (17.2) 6 (13) 6 (11.3) 13 (28.9) 5 (16.7) 0.10
Complicated courseg 74 (42.5) 18 (39.1) 15 (28.3) 31 (68.9) 10 (33.3) <0.01
Data are presented as median [first through third quartiles] or number (%)
ARDS acute respiratory distress syndrome, CAP community-acquired pneumonia; HCAP health care-associated pneumonia, HIV human immunodeficiency virus, ICU
intensive care unit, PSI Pneumonia Severity Index, SAPS Simplified Acute Physiologic Score, WHO World Health Organization.
ap values refer to differences between bacterial, viral, mixed, and no etiology groups in univariate logistic regression
bChronic disease included chronic dialysis, mellitus diabetes requiring oral medication and/or insulin, chronic heart failure classified NYHA 3 or 4, cirrhosis, chronic
respiratory failure requiring long-term oxygen therapy, and chronic immunosuppression
cPneumonia was considered health care-associated (HCAP) in the presence of at least one of the following conditions: hospitalization for ≥ 2 days in the preceding
90 days, institutionalization, chronic dialysis, and chronic immunosuppression
dTransfer from another ward included transfers from another ICU and from the medical wards
eAntibiotics before ICU admission referred to any administration of antibiotics, whatever drug regimen, before the ICU referral, i.e., in emergency departments or
in other medical wards
fThe follow-up duration was defined as the time between the date of the mPCR and the date of hospital discharge. If the patient was deceased in hospital, the
date of death was considered hospital discharge. If the patient was not deceased in hospital and the date of hospital discharge was not available, the date of ICU
discharge was considered hospital discharge gComplicated course was defined as hospital death and/or mechanical ventilation > 7 days
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on respiratory tract specimens. Elsewhere, the rate of
viral documentation reported in adult ICU patients with
CAP was slightly lesser, from 23 to 49 % [3–5].
Respiratory tract specimens for bacterial test were
recovered in a high proportion of patients (87.9 %),
including a LRT specimen in 68.4 % of patients. Bacterial
documentation was obtained in 52.3 % of patients, in
the range of other studies on ICU patients with CAP
(36–82 %) [3, 4]. Interestingly, the rate of bacteremia,
6.3 %, was markedly lower than usually observed [17, 18];
it might be attributable to a high pre-referral exposure to
antibiotics (44.3 %). Overall, 82.8 % of patients had a











S. pneumoniae 40 (23) 19 (41.3) - 21 (46.7) -
Other streptococci 6 (3.4) 2 (4.3) - 4 (8.9) -
S. aureus 12 (6.9) 6 (13) - 6 (13.3) -
L. pneumophila 8 (4.6) 7 (15.2) - 1 (2.2) -
C. pneumoniae – M. pneumoniae 6 (3.4) 5 (10.9) - 1 (2.2) -
H. influenzae 13 (7.5) 5 (10.9) - 8 (17.8) -
Enterobacteriaceae species 11 (6.3) 7 (15.2) - 4 (8.9) -
P. aeruginosa 7 (4) 2 (4.3) - 5 (11.1) -
Other bacteria 3 (1.7) 1 (2.2) - 2 (4.4) -
Mixed flora 10 (5.7) 6 (13) - 4 (8.9) -
Picornavirus (rhinovirus)a 22 (12.6) - 7 (13.2) 15 (33.3) -
Influenza A 32 (18.4) - 19 (35.8) 13 (28.9) -
Influenza B 6 (3.4) - 4 (7.5) 2 (4.4) -
Parainfluenza 3 (1.7) - 2 (3.8) 1 (2.2) -
Respiratory syncytial virus 9 (5.2) - 5 (9.4) 4 (8.9) -
Human metapneumovirus 12 (6.9) - 6 (11.3) 6 (13.3) -
Coronavirus 14 (8) - 7 (13.2) 7 (15.6) -
Adenovirus 3 (1.7) - 2 (3.8) 1 (2.2) -
Bocavirus 1 (0.6) - 1 (1.9) 0 (0) -
Cytomegalovirus 1 (0.6) - 1 (1.9) 0 (0) -
Herpes simplex virus 3 (1.7) - 1 (1.9) 2 (4.4) -
Varicella zoster virus 1 (0.6) - 1 (1.9) 0 (0) -
Data are presented as number (%)
CAP community-acquired pneumonia
aPicornavirus included rhinovirus and enterovirus
Table 3 Multivariate analysis of the risk factors for complicated
course in 174 patients with severe CAP
Variables OR 95 % CI p value
Microbiological diagnosis
Bacterial pneumonia Ref …
Viral pneumonia 0.69 0.24–1.95 0.48
Mixed pneumonia 3.15 1.12–8.83 0.03
No etiology pneumonia 1.29 0.40–4.21 0.67
Coronary artery disease 3.52 1.22–10.15 0.02
Shock on ICU admission 4.63 1.56–13.74 0.006
Lactate dehydrogenase > 245 U/L 4.27 1.55–11.78 0.005
PSI class IV-V at hospital referral 4.67 1.96–11.12 0.0005
CAP community-acquired pneumonia, ICU intensive care unit, OR odds ratio,
PSI Pneumonia Severity Index, Ref reference, 95 % CI = 95 %
confidence interval
Table 4 Risk factors for complicated course in patients with
severe CAP: multivariate analysis exploring the 91 patients with
either bacterial or mixed viral-bacterial infection
Variables OR 95 % CI p value
Microbiological diagnosis
Bacterial pneumonia Ref …
Mixed pneumonia 3.56 1.24–10.18 0.02
Coronary artery disease 2.59 0.60–11.19 0.20
Shock on ICU admission 5.63 1.53–20.73 0.009
Lactate dehydrogenase > 245 U/L 5.16 1.49–17.90 0.01
PSI class IV-V at hospital referral 2.69 0.76–9.51 0.13
CAP community-acquired pneumonia, ICU intensive care unit, Ref reference, OR
odds ratio, PSI Pneumonia Severity Index, 95 % CI 95 % confidence interval
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microbiological diagnosis, a high rate in line with that of
Karhu and colleagues [4].
The predominant viruses were influenza viruses and
picornavirus (rhinovirus) (21.8 % and 12.6 %, respect-
ively). Previous studies in ICU patients with CAP
reported a much lower rate of influenza infection, from
2 to 10 % [3–6]. It might be explained by low influenza
vaccine coverage in our population. Unfortunately, the
influenza vaccination history was usually not available in
medical records, preventing any conclusion on this
point. The incidence of rhinovirus was consistent with
that of previous reports [3, 5]. Interestingly, a “viral
phenotype” is emerging, mainly characterized by high
serum levels of creatine kinase, and high frequency of
alveolar-interstitial infiltrates on chest X-ray. It was not
yet reported, since previous works having largely used
mPCR in ICU patients with CAP did not specifically
record biology and radiographic data [3–6]. Chest X-ray
patterns, notably ground glass opacities, were consistent
with previous data [19]. Elevated levels of serum creatine
kinase could be attributable to the rhabdomyolysis
associated with viral infections, especially with influenza
and parainfluenza viruses [20]. The trend toward a high
serum level of cardiac troponin T in virus-infected
patients might suggest acute myocardial injury. Further-
more, alveolar-interstitial infiltrates could indicate pul-
monary edema. Unfortunately, brain natriuretic peptide
dosage and echocardiogram data were not available,
although left ventricular dysfunction has been previously
described in influenza A infection [21].
Virus-bacteria coinfection was observed in one patient
out of four, consistently with previous reports (9–39 %)
[3, 4, 22]. It was identified as independently associated
with a complicated course. This finding is original, since
previous works that studied CAP patients requiring ICU
admission did not point out any relationship between
viral-bacterial coinfection and severity [3, 4]. Karhu and
colleagues studied a limited cohort (n = 49), whereas
Choi and colleagues observed a low rate of virus-
bacteria coinfected patients in their cohort (18/198,
9 %), thus preventing any analysis on outcome in both
studies. In hospitalized patients with CAP, some data
suggested that the viral-bacterial coinfection might be
associated with high-risk classes of PSI [23], higher
length of hospital stay [24], and higher mortality [25].
More specifically, S. pneumoniae-influenza and S. pneu-
moniae-rhinovirus coinfections were correlated with a
more severe illness in hospitalized patients [22, 26, 27].
In our study, in order to avoid overinterpreting the data,
we decided to consider respiratory viruses as a homoge-
neous group of pathogens. This might be criticized,
since the pathogenicity probably differs from one viral
species to another. However, our results remained simi-
lar when taking into account non-influenza viruses only.
Further studies with larger populations may explore this
point, with comparing the prognosis of CAP patients
according to the type of virus as well as the different
virus-bacteria combinations. Our findings might have a
therapeutic impact. Currently, only very few medications
targeting non-influenza respiratory viruses are available
in clinical practice (cidofocir, ribavirine, immunoglobu-
lins). But some novel antiviral drugs, targeting mainly
respiratory syncytial virus and parainfluenza virus, have
shown promising results in immunocompromised
patients [28, 29] and in human volunteers [30]. Whether
these upcoming drugs would be of interest in virus-
infected CAP patients requiring ICU admission is
questionable. We identified the virus-bacteria coinfected
patients to be at risk of complicated ICU course, so
further studies might explore potential benefits of the
upcoming antiviral drugs in this high-risk population.
Our study has several limitations. First, this is a mono-
center study, so the generalization of our results should
be cautious. Second, this study included patients with
pneumonia that required ICU admission. It means that
we did not study mild to moderate pneumonia, prevent-
ing any conclusion on this population. Third, the study
was retrospective so we did not control the microbio-
logical investigations. By definition, a mPCR was per-
formed in the respiratory tract of every included patient
because it was the criteria for patient screening. But
some other microbiological testings were only occasion-
ally performed, i.e. cytomegalovirus and herpes simplex
virus PCR, or C. pneumoniae and M. pneumoniae
antibodies testing. Furthermore, the retrospective design
prevented us obtaining a number of data, which were
rarely reported in medical records by physicians, includ-
ing vaccine history, symptoms before hospital referral,
and duration of symptoms before ICU admission.
Fourth, only patients having undergone a mPCR in the
respiratory tract within the 72 hours following their ICU
admission were screened; this might suggest a confound-
ing of indication. Fifth, we chose a composite endpoint,
decided a priori. Indeed, considering the predictable low
hospital mortality, we did not choose hospital death as
primary endpoint, because the low frequency of the
event (death) would have favored the absence of signifi-
cant difference between groups. Sixth, we made the
assumption that a virus identified with PCR was a
causative pathogen of the pneumonia. This might be
criticized since respiratory viruses might be present in
asymptomatic adult subjects [7, 8]. Seventh, almost half
the patients (n = 77, 44.3 %) received antibiotics prior to
ICU admission. Thus some patients may have had false--
negative findings regarding bacterial infection and may
have been falsely included in the viral group instead of
the mixed group or to the no etiology group instead of
the bacterial group.
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Conclusions
Viruses are frequently identified in the respiratory tract
of patients with pneumonia requiring ICU admission,
with a strong predominance of influenza and rhinovirus.
The viral-bacterial coinfection concerns more than a
quarter of patients and is associated with an impaired
radiological and biological presentation and with a
complicated course.
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